Nurix Therapeutics (NRIX)
(Real Time Quote from BATS)
$12.79 USD
+0.43 (3.48%)
Updated Apr 29, 2024 10:40 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Nurix Therapeutics, Inc falls in the month of November.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -143.95 | -180.36 | -117.19 | -43.24 | -21.70 |
Depreciation/Amortization & Depletion | 8.23 | 11.23 | 7.79 | 2.45 | 2.25 |
Net Change from Assets/Liabilities | 20.12 | -19.02 | 9.11 | 36.41 | 19.55 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 34.23 | 28.34 | 15.93 | 4.30 | 0.51 |
Net Cash From Operating Activities | -81.37 | -159.81 | -84.37 | -0.08 | 0.60 |
Property & Equipment | -8.40 | -12.24 | -5.66 | -4.55 | -1.65 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 76.70 | 39.44 | -102.59 | -249.85 | 10.15 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 68.30 | 27.20 | -108.25 | -254.40 | 8.50 |
Uses of Funds
11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 3.22 | 22.43 | 153.88 | 339.02 | 0.13 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 94.76 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 3.22 | 117.19 | 153.88 | 339.02 | 0.13 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -9.85 | -15.42 | -38.73 | 84.54 | 9.23 |
Cash at Beginning of Period | 65.38 | 80.79 | 119.53 | 34.99 | 25.76 |
Cash at End of Period | 55.53 | 65.38 | 80.79 | 119.53 | 34.99 |
Diluted Net EPS | -2.65 | -3.71 | -2.73 | -2.76 | -6.59 |
Fiscal Year End for Nurix Therapeutics, Inc falls in the month of November.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | 2/28/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -41.52 | -143.95 | -101.99 | -65.01 | -40.73 |
Depreciation/Amortization & Depletion | 1.96 | 8.23 | 6.44 | 4.71 | 2.36 |
Net Change from Assets/Liabilities | -10.21 | 20.12 | -38.70 | -23.92 | -18.62 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.82 | 34.23 | 26.19 | 17.30 | 8.54 |
Net Cash From Operating Activities | -41.95 | -81.37 | -108.05 | -66.92 | -48.45 |
Property & Equipment | -2.88 | -8.40 | -5.82 | -3.36 | -2.28 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 38.40 | 76.70 | 88.49 | 63.26 | 18.35 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 35.51 | 68.30 | 82.67 | 59.90 | 16.07 |
Uses of Funds
2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | 2/28/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.62 | 3.22 | 3.21 | 1.51 | 1.48 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 1.62 | 3.22 | 3.21 | 1.51 | 1.48 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -4.81 | -9.85 | -22.17 | -5.52 | -30.90 |
Cash at Beginning of Period | 55.53 | 65.38 | 65.38 | 65.38 | 65.38 |
Cash at End of Period | 50.71 | 55.53 | 43.21 | 59.86 | 34.47 |
Diluted Net EPS | -0.76 | -0.77 | -0.68 | -0.45 | -0.75 |